AI For Pharma Growth

Dr Andree Bates

AI For Pharma Growth is the podcast from pioneering Artificial Intelligence entrepreneur Dr. Andree Bates created to help Pharma, Biotech and other Healthcare companies understand how the use of AI-based technologies can easily save them time and grow their brands and company results. This show blends deep experience in the sector with demystifying AI for biopharma execs from biotech start-ups right through to big pharma. In this podcast, Dr Andree will teach you the tried and true secrets to building results in a pharma company using AI and alert you to some fascinating new tools and applications to benefit you and your company. As the author of many peer-reviewed journals in pharma AI, and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI, futuretech, healthcare and pharma to help you to navigate through the, sometimes confusing, but magical world of AI powered tools to achieve real-world results. This podcast features many experts who have developed powerful AI-powered tools that are the secret behind some time-saving and supercharged revenue-generating business results. Those who share their stories and expertise show how AI can be applied to Discovery, R&D, clinical trials, market access, medical affairs, regulatory, market research, business insights, sales, marketing, including digital marketing, and so much more.

  1. 4d ago

    E244: What 10 years of building an AI Diagnostic start up teaches about real world AI vs lab AI

    In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dejan Nenov of Lumanix about what a decade of building AI diagnostics has taught him about the difference between laboratory performance and real-world clinical utility. Dejan explains how Lumanix began with a simple observation: dogs can detect disease from urine. By combining gas chromatography with machine learning, the team set out to recreate that capability in a repeatable, scalable diagnostic platform. The conversation explores why real-world diagnostic AI needs far more than a high validation score. Lumanix tests across symptomatic patients, controls and people with other conditions, while accounting for variables such as diet, hydration, medication and instrument drift. The goal is not simply to build a model that performs well on clean data, but one that holds up when reality gets messy. Dejan also explains Lumanix's biomarker-agnostic approach, where machine learning can identify useful patterns across thousands of metabolic data points without first requiring years of traditional biomarker discovery. The same platform could potentially support early screening, patient stratification and companion diagnostics. The key message is that reproducibility, disciplined validation and solving a real clinical problem matter far more than building an impressive demo. Topics Covered Lab AI versus real-world AI Metabolic digital twins from urine Gas chromatography and machine learning Signal versus noise in metabolomics Biomarker-agnostic diagnostics Patient stratification and companion diagnostics Reproducibility and independent validation What separates a real platform from a good demo About EularisEularis builds AI capability inside pharma and biotech - over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies. Keynotes and live sessions - Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work. The AI Enablement Institute - Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges. AI Strategic Blueprint and Governance - Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny. AI Custom Builds for BioPharma - Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint. Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.com About the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma. Dr. Andree Bates LinkedIn | Facebook | X

    E244: What 10 years of building an AI Diagnostic start up teaches about real world AI vs lab AI
  2. Nov 11

    E243: Rewiring Judgment: Why Pharma AI Fails as a Human Problem, Not a Technical One

    In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr Eugene Chan of Behavieural about why many AI failures in pharma are not really technical failures at all.  They are human problems involving trust, judgement, behaviour and adoption. Eugene explains that even when the technology works, people may ignore it, override it or over-trust it. Clinicians, scientists and executives bring their own biases, habits, incentives and sense of professional identity to every AI-assisted decision. The conversation explores why autonomy matters, how cognitive load changes behaviour, and why one incorrect AI output can damage trust far beyond that single mistake. Eugene also discusses automation bias, the risks of simply clicking approve, and why explainability needs to help judgement rather than replace it. They also look at change management and why one-off training is not enough. If organisations want AI adoption to stick, behavioural interventions need to become part of workflow design, governance and organisational culture. The key message is that having the best model, policy or governance framework is not enough if it assumes people will behave rationally. Behavieural - https://behavieural.com/  Topics Covered Why pharma AI adoption is a behavioural problem Trusting and distrusting AI Automation bias and over-reliance Professional identity and autonomy Cognitive load and decision making Why one bad output can damage long-term trust Human judgement versus AI recommendations Change management and behaviour change Designing governance around real human behaviour About Eularis Eularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies. Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work. The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges. AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny. AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint. Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.com About the Podcast AI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma. Dr. Andree Bates LinkedIn | Facebook | X

    E243: Rewiring Judgment: Why Pharma AI Fails as a Human Problem, Not a Technical One
  3. Nov 4

    E242: The diagnostic room: HTA Expectations for AI-Generated Evidence: NICE, CDA-AMC and the EU JCA Principles

    In this solo episode of AI For Pharma Growth, Dr Andree Bates explores what health technology assessment bodies now expect when AI is used to generate, analyse or support evidence. The episode looks at the emerging principles from NICE in England, CDA-AMC in Canada and the EU Joint Clinical Assessment framework. While none of these bodies has banned AI, Andree explains that organisations are increasingly expected to be able to justify where AI was used, how it was used, who was responsible for checking it and whether the process can be reconstructed. She breaks the expectations into four core areas: accountability, human oversight, transparency and reporting. That includes recording tools, versions, dates, prompts, adaptations and the specific role AI played in screening, extraction, analysis or reporting. Andree also highlights one of the biggest practical risks: automation bias. Human oversight cannot simply mean somebody glanced at the output. It means having a named person who can explain what was checked, how it was checked and why the level of verification was appropriate for that task. The key message is that AI can still accelerate evidence generation, but teams now need the documentation and governance to defend its use. Topics Covered NICE, CDA-AMC and EU JCA expectations Accountability for AI-assisted evidence Human oversight and automation bias Declaring AI tools and methods Recording prompts, versions and outputs Screening versus extraction risk Copyright, data protection and security AI use across vendors and CROs Building an audit trail before submission What assessors may ask next About EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies. Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work. The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges. AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny. AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint. Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.com About the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma. Dr. Andree Bates LinkedIn | Facebook | X

    E242: The diagnostic room: HTA Expectations for AI-Generated Evidence: NICE, CDA-AMC and the EU JCA Principles
  4. Oct 28

    E241: Beyond the Survey: How Generative AI Captures the Patient Voice at Scale — and Why It's Pharma's Next Growth Lever

    In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Mattia Marco Caruson, co-founder and CEO of mama health, about how generative AI is changing the way pharma understands the patient journey. Mattia explains why traditional methods such as surveys, focus groups and clinician interviews often capture only fragments of what patients actually experience. In rare and chronic diseases, the most important parts of the journey can happen between appointments, long before a patient reaches the right doctor or treatment. The conversation explores how generative AI can enable open-ended conversations with patients at scale and then turn those qualitative stories into structured, analysable data. Instead of forcing people to reduce years of lived experience to a multiple-choice answer, AI can help capture their own words, frustrations, unmet needs and decision points. Mattia also discusses how these insights can influence launch strategy, positioning, patient support, medical affairs and market access. He argues that pharma should stop viewing AI only as a way to make existing processes faster and start asking what entirely new capabilities it unlocks. They also examine consent, privacy, hallucination risk and the need to ground patient-facing AI in trusted medical sources. Topics Covered Why surveys miss important parts of the patient journey AI-powered patient conversations at scale Turning qualitative stories into structured insight Understanding unmet needs and treatment decisions Patient insight for launch and commercial strategy Consent, privacy and data governance Grounding AI in trusted medical knowledge Why pharma needs to listen directly to patients About EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies. Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work. The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges. AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny. AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint. Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.com About the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma. Dr. Andree Bates LinkedIn | Facebook | X

    E241: Beyond the Survey: How Generative AI Captures the Patient Voice at Scale — and Why It's Pharma's Next Growth Lever
  5. Oct 20

    E240: How secure and compliant data collaboration accelerates research and medical science

    In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Kurt Rohloff, co-founder and CEO of Duality Technologies, about how privacy-enhancing technologies could unlock data collaboration without forcing organisations to give up control of sensitive information. Kurt explains how technologies such as fully homomorphic encryption and federated learning allow organisations to analyse encrypted or distributed data without exposing the underlying patient information. For pharma and medical research, that creates opportunities to reuse existing data, collaborate across organisations and geographies, and access populations that have historically been difficult to include. The conversation explores why data security should not be viewed only as a compliance cost. Secure collaboration can also become a value creator, helping organisations run better science, reduce administrative overhead and generate evidence that would otherwise be too expensive or difficult to obtain. They also discuss rare diseases, underserved communities, cross-border research and the role regulators and standards bodies will play in enabling wider adoption. Kurt argues that the technology is often further ahead than organisational acceptance, making policy conversations just as important as technical development. Topics Covered Privacy-enhancing technologies in pharma Fully homomorphic encryption Federated learning and secure analytics Reusing clinical and research data Cross-border collaboration Rare diseases and underserved populations Data sovereignty and regulatory acceptance Secure AI and LLM workloads About Eularis Eularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies. Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work. The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges. AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny. AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint. Start with the Institute → https://eularis.com/institute/ Everything else → https://eularis.com About the Podcast AI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma. Dr. Andree Bates LinkedIn | Facebook | X

    E240: How secure and compliant data collaboration accelerates research and medical science
  6. Oct 13

    E239: How to Speed Up Drug Development Without Compromising Compliance

    In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Clara Bernardes, co-founder and CSO of Biorce, about how AI can accelerate clinical development without sacrificing compliance or scientific rigour. Biorce was born from a deeply personal experience. After Clara's father-in-law received a terminal melanoma diagnosis, access to a clinical trial through compassionate use extended his life from an expected three months to more than a year. That experience shaped Biorce's mission: reduce the time it takes promising treatments to reach patients. Clara explains why clinical trials are still slowed by protocol amendments, patient identification problems, poorly designed criteria and human-led errors that could often be caught much earlier. The conversation explores how Biorce uses AI and almost one million annotated protocols to support protocol development, learn from previous trial amendments and provide clear rationale for recommendations. Clara also discusses why transparency, AI ethics and keeping humans in the loop are essential in regulated clinical development. The key message is that speed and compliance do not have to be opposing forces. The goal is not to replace scientists or investigators, but to give them better information faster while preserving human judgement. Topics Covered Why clinical trials start late Protocol amendments and avoidable human error AI-generated clinical trial protocols Learning from previous trial failures Transparency and explainability AI ethics and regulatory compliance Keeping humans in the loop Balancing quality with velocity What sponsors should ask AI vendors About Eularis Eularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies. Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work. The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges. AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny. AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint. Start with the Institute → https://eularis.com/institute/ Everything else → https://eularis.com About the Podcast AI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma. Dr. Andree Bates LinkedIn | Facebook | X

    E239: How to Speed Up Drug Development Without Compromising Compliance
  7. Oct 6

    E238: The diagnostic room: The Fifteen Failures Only Human Judgement Catches

    In this solo episode of AI For Pharma Growth, Dr Andree Bates explores one of the biggest blind spots in pharma AI: the failures that can survive a normal review process even when the output sounds polished, plausible and well grounded. Dr Andree explains why better models and better retrieval do not remove the need for human judgement. In fact, as AI systems improve, people often scrutinise them less. Fluent prose can create a false sense of reliability, while automation bias and anchoring make reviewers less likely to challenge the underlying frame. The episode introduces three broad families of failure: invented, distorted and misdirected. These include fabricated or misattributed citations, silent interpolation, dropped qualifiers, hedge-to-claim escalation, manufactured consensus, stale guidance and planted instructions. Many of these are harder to catch because the output reads better than the truth. Dr Andree also shares practical checks teams can use, including tracing claims back to source, checking what is unsupported, looking for missing qualifiers, regenerating outputs for stability and deliberately testing the opposite case. The key message is that prompting is only half the skill. In a regulated industry, teams also need to be trained to judge what comes back. Topics Covered Why better AI can lead to less scrutiny Automation bias and anchoring Invented, distorted and misdirected failures Fabricated and misattributed citations Dropped qualifiers and strengthened claims Manufactured consensus Prompt injection and planted instructions Claim-by-claim verification Why review methods must change for AI The growing importance of the judgement layer About EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies. Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work. The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges. AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny. AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint. Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.com About the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma. Dr. Andree Bates⁠⁠ LinkedIn⁠⁠ |⁠⁠ Facebook⁠⁠ |⁠⁠ X

    E238: The diagnostic room: The Fifteen Failures Only Human Judgement Catches
  8. Sep 29

    E237: Beyond the Pill: How AI is Unlocking the Preventative Medicine Opportunity Pharma Can't Afford to Miss

    In this episode of AI For Pharma Growth, Dr Andree Bates speaks with cancer biologist and health educator Rebecca Maff about how AI could help shift healthcare from treating disease to preventing it. Rebecca’s interest in prevention began after seeing women in her own family diagnosed with late-stage cancers and serious autoimmune conditions. Her subsequent work has included machine learning models designed to identify patients at higher risk of cancers and encourage overdue screening before disease progresses. The conversation explores what prevention really means in practice, from early biomarkers and personalised risk modelling to screening, lifestyle, metabolic health and behavioural change. Rebecca explains how AI can help analyse electronic health records and large patient populations to identify signals that would be difficult for humans to find manually. They also discuss the commercial opportunity for pharma. If late-stage disease becomes more preventable, the industry may need to think beyond treating established illness and consider new models built around earlier detection, intervention and maintaining health. Trust remains a major challenge. Rebecca argues that patients and clinicians need to see credible, successful AI implementations before confidence grows, particularly when systems are using highly personal health, genomic and behavioural data. Topics Covered Moving healthcare upstream towards prevention AI-powered cancer risk stratification Early screening and disease detection Biomarkers and personalised risk Using electronic health records to identify signals Prevention as a future pharma opportunity Lifestyle, metabolic health and chronic disease Patient data, privacy and trust in AI Why proof of concept matters before scaling About EularisEularis builds AI capability inside pharma and biotech — over 20 years applying AI to real pharmaceutical problems, inside real pharmaceutical and biotech companies. Keynotes and live sessions — Working sessions for pharma teams where nobody leaves with notes. They leave with working prompts and real capability they've already run on their own work. The AI Enablement Institute — Strategy and a workshop get you started; neither stays current. Most pharma companies already have a generic AI course library. None of it is written for a regulatory writer, an MSL or a market access lead trying to get today's work done. Training is an event; enablement is capability that stays current. The Institute runs shared foundations for the regulated constraints, then tracks by business unit function, with new content monthly, live office hours with Dr Andree Bates, and per-person records a sponsor can show an auditor. One price per business unit, no per-seat charges. AI Strategic Blueprint and Governance — Board-ready strategy that links initiatives to commercial outcomes, with the sequencing, governance, capability and financial logic to survive scrutiny. AI Custom Builds for BioPharma — Design and build of the AI solutions that make strategic sense in your operating reality, tied back to the Blueprint. Start with the Institute → https://eularis.com/institute/Everything else → https://eularis.com About the PodcastAI For Pharma Growth is the podcast from Dr Andree Bates, helping pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands and improve company results. The show demystifies AI for biopharma leaders, from start-up biotech through to Big Pharma. Dr. Andree Bates LinkedIn | Facebook | X

    E237: Beyond the Pill: How AI is Unlocking the Preventative Medicine Opportunity Pharma Can't Afford to Miss

Ratings & Reviews

3.7
out of 5
10 Ratings

About

AI For Pharma Growth is the podcast from pioneering Artificial Intelligence entrepreneur Dr. Andree Bates created to help Pharma, Biotech and other Healthcare companies understand how the use of AI-based technologies can easily save them time and grow their brands and company results. This show blends deep experience in the sector with demystifying AI for biopharma execs from biotech start-ups right through to big pharma. In this podcast, Dr Andree will teach you the tried and true secrets to building results in a pharma company using AI and alert you to some fascinating new tools and applications to benefit you and your company. As the author of many peer-reviewed journals in pharma AI, and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI, futuretech, healthcare and pharma to help you to navigate through the, sometimes confusing, but magical world of AI powered tools to achieve real-world results. This podcast features many experts who have developed powerful AI-powered tools that are the secret behind some time-saving and supercharged revenue-generating business results. Those who share their stories and expertise show how AI can be applied to Discovery, R&D, clinical trials, market access, medical affairs, regulatory, market research, business insights, sales, marketing, including digital marketing, and so much more.

You Might Also Like